Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Ferro

Showing results (1-10 of 420) with videos related to

Pageof 42
Sort By:
Translational Andrology and Urology|October 28, 2016
Multi-omics approach reveals the secrets of metabolism of clear cell-renal cell carcinomaGiuseppe Lucarelli, Matteo Ferro, Michele Battaglia
Diagnostics (Basel, Switzerland)|March 3, 2021
High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-OncologyGiorgio Napodano, Matteo Ferro, Roberto Sanseverino
BJU International|December 20, 2011
Sipuleucel-T (Provenge®) for castration-resistant prostate cancerGiuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba
Expert Review of Anticancer Therapy|December 21, 2010
Sipuleucel-T for prostate cancer: the immunotherapy era has commencedCarlo Buonerba, Matteo Ferro, Giuseppe Di Lorenzo
Expert Review of Anticancer Therapy|February 29, 2012
How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoidedGiuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba
International Journal of Urology : Official Journal of the Japanese Urological Association|August 13, 2020
Editorial Comment from Dr Bertolo et al. to Partial nephrectomy preserves renal function without increasing the risk of complications compared with radical nephrectomy for renal cell carcinomas of stages pT2-3aRiccardo Bertolo, Chiara Cipriani, Matteo Ferro, et al.
Journal of Basic and Clinical Physiology and Pharmacology|September 25, 2021
Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicineFelice Crocetto, Amelia Cimmino, Matteo Ferro, et al.
Minerva Urology and Nephrology|October 23, 2025
Comment on: "The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach"Sara Palumbo, Matteo Ferro, Savio D Pandolfo, et al.
Urologia|April 6, 2013
[How to apply follow-up in relation to risk group]Vittorino Montanaro, Antonio Di Girolamo, Matteo Ferro, et al.
Diagnostics (Basel, Switzerland)|August 23, 2020
MRI and Active Surveillance for Prostate CancerAngelo Porreca, Michele Colicchia, Gian Maria Busetto, et al.
Pageof 42

Showing results (1-10 of 420) with videos related to

Sort By:
Pageof 42
Translational Andrology and Urology|October 28, 2016
Multi-omics approach reveals the secrets of metabolism of clear cell-renal cell carcinomaGiuseppe Lucarelli, Matteo Ferro, Michele Battaglia
Diagnostics (Basel, Switzerland)|March 3, 2021
High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-OncologyGiorgio Napodano, Matteo Ferro, Roberto Sanseverino
BJU International|December 20, 2011
Sipuleucel-T (Provenge®) for castration-resistant prostate cancerGiuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba
Expert Review of Anticancer Therapy|December 21, 2010
Sipuleucel-T for prostate cancer: the immunotherapy era has commencedCarlo Buonerba, Matteo Ferro, Giuseppe Di Lorenzo
Expert Review of Anticancer Therapy|February 29, 2012
How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoidedGiuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba
International Journal of Urology : Official Journal of the Japanese Urological Association|August 13, 2020
Editorial Comment from Dr Bertolo et al. to Partial nephrectomy preserves renal function without increasing the risk of complications compared with radical nephrectomy for renal cell carcinomas of stages pT2-3aRiccardo Bertolo, Chiara Cipriani, Matteo Ferro, et al.
Journal of Basic and Clinical Physiology and Pharmacology|September 25, 2021
Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicineFelice Crocetto, Amelia Cimmino, Matteo Ferro, et al.
Minerva Urology and Nephrology|October 23, 2025
Comment on: "The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach"Sara Palumbo, Matteo Ferro, Savio D Pandolfo, et al.
Urologia|April 6, 2013
[How to apply follow-up in relation to risk group]Vittorino Montanaro, Antonio Di Girolamo, Matteo Ferro, et al.
Diagnostics (Basel, Switzerland)|August 23, 2020
MRI and Active Surveillance for Prostate CancerAngelo Porreca, Michele Colicchia, Gian Maria Busetto, et al.
Pageof 42